Cargando…

Early diarrhoea under sorafenib as a marker to consider the early migration to second‐line drugs

BACKGROUND: Despite atezolizumab and bevacizumab (A + B) is currently the first‐line treatment for hepatocellular carcinoma (HCC) patients, some patients will not be adequate for this combination. In the setting of sorafenib some adverse events have been proposed as prognostic factors. OBJECTIVE: To...

Descripción completa

Detalles Bibliográficos
Autores principales:	Díaz‐González, Álvaro, Sapena, Víctor, Boix, Loreto, Torres, Ferrán, Sanduzzi‐Zamparelli, Marco, Da Fonseca, Leonardo G., LLarch, Neus, Iserte, Gemma, Guedes, Cassia, Muñoz‐Martínez, Sergio, Darnell, Anna, Belmonte, Ernest, Rimola, Jordi, Forner, Alejandro, Ayuso, Carmen, Bruix, Jordi, Reig, María
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Hepatobiliary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280813/ https://www.ncbi.nlm.nih.gov/pubmed/34228394 http://dx.doi.org/10.1002/ueg2.12111

Ejemplares similares

Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma
por: Corominas, Josep, et al.
Publicado: (2021)

Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients—A Multiparametric Prediction
por: Muñoz-Martínez, Sergio, et al.
Publicado: (2023)

Portal Hypertension may Influence the Registration of Hypointensity of Small Hepatocellular Carcinoma in the Hepatobiliary Phase in Gadoxetic Acid MR
por: Caparroz, Carla, et al.
Publicado: (2022)

Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity
por: da Fonseca, Leonardo G., et al.
Publicado: (2021)

Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib
por: Sapena, Víctor, et al.
Publicado: (2022)

Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents
por: Sanduzzi-Zamparelli, Marco, et al.
Publicado: (2019)

Controversies in the management of hepatocellular carcinoma
por: Forner, Alejandro, et al.
Publicado: (2019)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib
por: Colagrande, S., et al.
Publicado: (2020)

Plasma procalcitonin may be an early predictor of liver injury in acetaminophen poisoning: A prospective cohort study
por: Nuzzo, Alexandre, et al.
Publicado: (2021)

Glucose variability during the early course of acute pancreatitis predicts two‐year probability of new‐onset diabetes: A prospective longitudinal cohort study
por: Bharmal, Sakina H., et al.
Publicado: (2022)

miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: de la Cruz-Ojeda, Patricia, et al.
Publicado: (2022)

Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma
por: Tutusaus, Anna, et al.
Publicado: (2018)

Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
por: Saha, Supriya K., et al.
Publicado: (2016)

Next‐Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma
por: Ikeda, Sadakatsu, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
por: Liu, Xiufeng, et al.
Publicado: (2019)

Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment‐Related Adverse Events From the CheckMate 040 Study
por: Julien, Karen, et al.
Publicado: (2020)

Correlation of liver-to-spleen ratio, lung CT scores, clinical, and laboratory findings of COVID-19 patients with two consecutive CT scans
por: Guler, Ezgi, et al.
Publicado: (2020)

Feasibility and safety of bedside percutaneous biliary drainage in patients with severe cholangitis
por: Gupta, Pankaj, et al.
Publicado: (2020)

Higher frequency of hepatic steatosis at CT among COVID-19-positive patients
por: Medeiros, Augusto Kreling, et al.
Publicado: (2020)

CT of amebic liver abscess: different morphological types with different clinical features
por: Priyadarshi, Rajeev Nayan, et al.
Publicado: (2021)

The natural course of giant paraesophageal hernia and long-term outcomes following conservative management
por: Oude Nijhuis, Renske A B, et al.
Publicado: (2020)

Clinical management of patients with drug‐induced liver injury (DILI)
por: Björnsson, Einar S.
Publicado: (2021)

Impact of thyroid disorders on the incidence of non‐alcoholic fatty liver disease in Germany
por: Labenz, Christian, et al.
Publicado: (2021)

Inhibition of NAE‐dependent protein hyper‐NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease
por: Lee‐Law, Pui Y., et al.
Publicado: (2021)

Neoadjuvant Treatment with Angiogenesis‐Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study
por: Woei‐A‐Jin, F.J. Sherida H., et al.
Publicado: (2021)

Integrated prognostication of intrahepatic cholangiocarcinoma by contrast-enhanced computed tomography: the adjunct yield of radiomics
por: Silva, Mario, et al.
Publicado: (2021)

Prospective assessment of diagnostic efficacy and safety of Sonazoid(TM) and SonoVue(®) ultrasound contrast agents in patients with focal liver lesions
por: Lv, Ke, et al.
Publicado: (2021)

Referral care paths for non‐alcoholic fatty liver disease—Gearing up for an ever more prevalent and severe liver disease
por: van Dijk, Anne‐Marieke, et al.
Publicado: (2021)

High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort
por: Llop, Elba, et al.
Publicado: (2021)

Real-time virtual sonography-assisted radiofrequency ablation in liver tumors with conspicuous or inconspicuous images or peritumoral landmarks under ultrasonography
por: Huang, Hsin-Chih, et al.
Publicado: (2021)

Portosystemic shunt surgery in the era of TIPS: imaging-based planning of the surgical approach
por: Fehrenbach, Uli, et al.
Publicado: (2020)

CT angiography of abdomen and pelvis in critically ill COVID-19 patients: imaging findings and correlation with the CT chest score
por: Vadvala, Harshna V., et al.
Publicado: (2021)

Spectrum of Fontan-associated liver disease assessed by MRI and US in young adolescents
por: Thrane, Karl Julius, et al.
Publicado: (2021)

Screening of radiotracer for diagnosis of colorectal cancer liver metastasis based on MACC1-SPON2
por: Jiang, Hao, et al.
Publicado: (2021)

Epidemiology of pyogenic liver abscesses in Germany: Analysis of incidence, risk factors and mortality rate based on routine data from statutory health insurance
por: Zimmermann, Lisa, et al.
Publicado: (2021)

Reproducibility of liver R2* quantification for liver iron quantification from cardiac R2* acquisitions
por: Muehler, M. R., et al.
Publicado: (2021)

Repeatability and reproducibility of deep-learning-based liver volume and Couinaud segment volume measurement tool
por: Mojtahed, Amirkasra, et al.
Publicado: (2021)

Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization
por: Müller, Lukas, et al.
Publicado: (2021)

Clinical management of chronic hepatitis B: A concise overview
por: Furquim d’Almeida, Arno, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ek2j3dnpg2fm9mllr0n2kpjeod